RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:97560

Primary membranous glomerulonephritis

low confidenceDisorder

Also known as: Idiopathic membranous glomerulonephritis · Primary membranous nephropathy

Publications

1,545

Trials

33

Interventional, condition-specific

Researchers

1,013

Distinct authors in sample

Gene link

—

Readiness

4/6

Stages with a signal

Clinical definition (Orphanet)

A rare glomerular disease, histologically characterized by thickening of the capillary wall, with immune deposits predominantly containing IgG4 and C3 on the sub-epithelial side, and typically manifesting with nephrotic syndrome.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (1)

membranous nephropathy - Idiopathic

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

4/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    1,545 matched papers (1,194 in last 10 years) Source

  3. Phenotype characterisedPresent

    1 HPO annotations (e.g. Anti-phospholipase A2 receptor antibody positivity) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationPartial

    3 EMA designations (none yet with FDA orphan-indication approval) — e.g. rituximab Source

  6. Interventional trialPresent

    33 matched on ClinicalTrials.gov (20 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

1

Associated phenotypes · MONDO:0013860

  • Anti-phospholipase A2 receptor antibody positivity

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-27

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

3

Designations · no FDA orphan-indication approval yet

  • EMA rituximabTreatment of primary membranous nephropathy · 25/07/2023 · PositiveEMA designation
  • EMA povetaciceptTreatment of primary membranous nephropathy · 23/02/2026 · PositiveEMA designation
  • EMA FelzartamabTreatment of primary membranous nephropathy · 21/11/2025 · PositiveEMA designation

Sources: FDA OOPD · EMA orphan designations

Open Targets candidates

15

Drugs / clinical candidates · MONDO_0013860

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

1,545

1,545 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

1,545 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

1,194 in the last 10 years · low confidence

Phrase hits: 1,545 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,013

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Wang Y22 papers · 2026

    Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

    Papers in Europe PMC
  2. 02
    Li X10 papers · 2026

    Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

    Papers in Europe PMC
  3. 03
    Li Y10 papers · 2026

    Department of Nephrology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Institute of Nephrology, No.16766 Jingshi Road, Jinan, Shandong 250014, China.

    Papers in Europe PMC
  4. 04
    Liu Y10 papers · 2026

    Department of Nephrology, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China.

    Papers in Europe PMC
  5. 05
    Zhang Y10 papers · 2026

    Department of Nephrology, The First Affiliated Hospital of Soochow University, Suzhou, PR China.

    Papers in Europe PMC
  6. 06
    Chen Y9 papers · 2026

    Nephrology and Rheumatology Immunology Diagnosis and Treatment Center, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, 100010, China.

    Papers in Europe PMC
  7. 07
    Huang B9 papers · 2026

    College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China. jswxhb@163.com.

    Papers in Europe PMC
  8. 08
    Wan Q9 papers · 2026

    Cambridge Research Center, AbbVie Inc, Cambridge, MA, United States.

    Papers in Europe PMC
  9. 09
    Sun J8 papers · 2026

    Shandong Provincial Hospital, Shandong University, Jinan, China.

    Papers in Europe PMC
  10. 10
    Li S7 papers · 2026

    Nephrology department, Shanghai Changhai Hospital, The First Affiliated Hospital of Naval Medical University, 168 Changhai Road, Shanghai, 200082, China.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

33

interventional trials for this specific condition

33 interventional trials matched this specific condition name; 20 currently recruiting in our sample. 2 trials are registered for membranous glomerulonephritis, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 9 September 2026

33 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 96.2th percentile).

low confidence · 96.2th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

33 interventional trials matched after quoted-phrase search and title/condition post-filter.

Broader category: membranous glomerulonephritis

2

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Observational and natural-history studies

4 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 11 · after dedupe 11 · already on CT.gov 0 · kept 8 · parent 1 · uncertain 1 · dropped 1 · fetched 2026-07-27

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

Broader / parent-category hits (1)
Uncertain / not reviewed (1)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Primary membranous glomerulonephritis — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Primary membranous glomerulonephritis" OR "Idiopathic membranous glomerulonephritis" OR "Primary membranous nephropathy" OR "membranous nephropathy - Idiopathic"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Primary membranous glomerulonephritis" OR "Idiopathic membranous glomerulonephritis" OR "Primary membranous nephropathy" OR "membranous nephropathy - Idiopathic"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 33 interventional · 4 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"membranous glomerulonephritis"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (1545) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity

Ingested 2026-07-26T01:33:58.822Z